Ten-year APHINITY data show Perjeta-based regimen reduced the risk of death by 17% in people with HER2+ve early-stage breast cancer May 21, 2025
Ph 3 Trial of Disitamab Vedotin in 1L HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma meets Primary Endpoints of PFS and OS May 21, 2025
Ph 3 KEYNOTE-B96 Trial Met Primary PFS Endpoint in Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers May 21, 2025
Updated Ph 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the treatment of NHL Announced May 21, 2025
Two Ph 2 trials of Samuraciclib + SERDs in HR+ve Advanced Breast Cancer demonstrate extended PFS in patients without TP53 mutations or without liver mets May 21, 2025
IND application for Ph 1 trial of Penetrium™ in combination with docetaxel voluntary withdrawn May 21, 2025
FDA Clears IND for Ph 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need May 21, 2025
IND cleared for ERAS-0015 and IND submitted for ERAS-4001; Ph 1 monotherapy data for both programs expected in 2026 May 21, 2025
FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for B7-H3 CAR T-cell therapy for incurable pediatric brain tumors May 21, 2025
CPO301 granted the fast track designation by U.S. FDA for the treatment of adult patients with NSCLC May 21, 2025
FDA Approves Zynyz (retifanlimab-dlwr) for 1L Treatment of Advanced Anal Cancer Patients May 21, 2025
Blenrep (belantamab mafodotin) combinations approved in Japan for treatment of R/R multiple myeloma May 21, 2025
